phosphodiesterase inhibitor

(redirected from PDE4 inhibitor)

phosphodiesterase inhibitor

Abbreviation: PDE inhibitor
Any agent that blocks phosphodiesterase, inhibiting the production of second messengers within cells, such as cyclic adenosine monophosphate or cyclic glucose monophosphate. Drugs that inhibit PDE include sildenafil, an agent used to treat erectile dysfunction, and other agents used as positive inotropes and vasodilators in heart failure.
See also: inhibitor

phosphodiesterase inhibitor

positive inotrope (e.g. enoximone [Perfan]); see inotrope

inhibitor

1. any substance that interferes with a chemical reaction, growth or other biological activity.
2. a chemical substance that inhibits or checks the action of a tissue organizer or the growth of microorganisms.
3. an effector that reduces the catalytic activity of an enzyme.

coagulation i's
clotting factors.
fibrinolytic i's
clotting factors.
phosphodiesterase inhibitor
inhibits phosphodiesterase, which in turn inactivates cyclic adenosine monophosphate. The effect of the inhibitor is to increase the heart muscle content of cAMP.
reversible i's
pharmaceutical inhibitors which have only a temporary effect, e.g. the cholinesterase inhibitors neostigmine, physostigmine.
References in periodicals archive ?
M2 PHARMA-September 7, 2017-Medimetriks Study Shows Topical PDE4 Inhibitor Provides Early Itch Relief in Patients with Atopic Dermatitis
Anacor's flagship asset, crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, is currently under review by the US FDA for the treatment of mild-to-moderate atopic dermatitis, commonly referred to as eczema.
Anacors flagship asset, crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, is presently being reviewed by the U.
Materials and Methods: To investigate whether PDE4B regulates additional inflammatory mediators other than TNF-a, in this study we initially used two-dimensional gel electrophoresis approach to screen the secreted proteins that are modulated by the PDE4 inhibitor rolipram in LPS-stimulated Raw 264.
Upon completion of the transaction, AstraZeneca will own the development and commercial rights to Tudorza Pressair (aclidinium bromide inhalation powder), a twice-daily long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD), and Daliresp (roflumilast), a once-daily oral PDE4 inhibitor currently on the market for COPD.
Additionally, AstraZeneca will own the development and commercial rights in the US and Canada Daliresp (roflumilast), the only once-daily oral PDE4 inhibitor currently on the market for COPD.
Apremilast is an oral PDE4 inhibitor that modulates cyclic AMP metabolism and in inflammatory cells results in decreased production of pro-inflammatory mediators, such as TNF, IL17, and IL23, and increased production of anti-inflammatory mediators, such as IL10.
In the first half of 2010, the company reported early clinical data for its two anti-inflammatory programmes, proprietary VAP-1 antibody and third generation PDE4 inhibitor ronomilast.
The PDE4 inhibitor, which was discovered by Tanabe Seiyaku, has a property of inhibiting the activity of inflammatory cells.
Novel therapies aimed at alternative targets such as interleukin 12/23 (IL-12/23), interleukin-17 (IL-17), interleukin-6 (IL-6), phosphodiesterase type 4 (PDE4) and janus kinase (JAK) are in active development, with a PDE4 inhibitor and an anti-IL-12/23 closest to approval for PsA.
The agreement, announced in December 2015, includes the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease.
The Oral options- JAK inhibitors led by PFE's Tofacitinib and CELG's PDE4 inhibitor, Apremilast.